Dr Reddys unveils Posaconazole delayed-release tablets in US
Hyderabad: Drugmaker, Dr Reddy's Laboratories Ltd. has announced the launch of Posaconazole Delayed-Release Tablets, 100 mg in the U.S. Market.
The product is a therapeutic generic equivalent to NOXAFIL (posaconazole) Delayed-Release Tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).
Posaconazole is an azole antifungal indicated as follows:
Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
The NOXAFIL brand and generic had U.S. sales of approximately $140.8 million MAT for the most recent twelve months ending in February 2022 according to IQVIA.
Dr Reddy's Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60.
Read also: Dr Reddys, MediCane Health introduce medical cannabis products in Germany
Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddys unveils Methylprednisolone Sodium Succinate for Injection in US
